# Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

> **NCT00059982** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group**

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** perifosine

## Key facts

- **NCT ID:** NCT00059982
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00059982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00059982, "Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00059982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*